水肿2013年0902版

给药方案 MPFF VS安慰剂（18 vs 18例）
MPFF治疗后水肿缓解程度 裸关节周长 小腿周长 体积
+++
+++
MPFF VS 安慰剂（76 vs 74例） +++
MPFF VS 单方地奥司明（4345例）+++
开放性研究（20例）
开放性研究（200例）
+
开放性研究（3101例）
+++ +++
Katherine A. Lyseng-Williamson，et al. Micronised Purified Flavonoid Fraction A Review of its Use in Chronic Venous Insufficiency, Venous Ulcers and Hemorrhoids .Drugs 2003; 63 (1): 71-100
爱脉朗®双重成分协同，抗炎消肿更强效
Paysant J, et al. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation.intAngiol.2008; 27:81-85.
局部水肿分类
常见类别
疾病/发病率
静脉性水肿
• 慢性静脉性疾病（发病率：3%-11%） • 血栓性静脉炎
淋巴性水肿 炎症性水肿
• 淋巴管炎（丝虫病） • 乳腺癌术后（上肢水肿发病率：15%-20%）
• 炎症/局部感染 • 创伤 • 烧伤
James G.O. Brien, et al, Treatment of edema, American Family Physician, June 1,2005,Vol 71,Number 11 Perrin M, Ramelet AA. Pharmacological Treatment of Primary CVD , Eur J Vasc Endovasc Surg. 2011;41:117-125
爱脉朗®显著改善静脉性水肿临床文献
文献
Chassignolle et al,1987 Gilly et al,1994 Cospite et al,1989
Blume et al,1992 Laurent et al,1988 Jantet,2002 + P < 0.05 +++ P < 0.001
爱脉朗®减轻水肿显著优于其他静脉活性药物
静脉活性药物缓解踝部水肿荟萃分析
Allaert FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol.2012 Aug; 31(4):310-5..
水肿的发病机制
1. Bergan JJ, et al. Chronic venous disease. N Engl J Med. 2006; 355:488-498. 2. Bergan JJ, et al. Pathogenesis of primary chronic venous disease: insights from animal models of venous hypertension. J
Pain Symptom Manage 1992; 7:110-6.
静脉活性药物治疗水肿的疗效和地位： 获权威临床证据证实
Cochrane系统评价静脉活性药物治疗水肿 • 纳入44篇文献（n=4413）
结果显示：静脉活性药物显著改善静脉性水肿
(RR 0.72，95% CI 0.65; 0.81)
爱脉朗®作用三大系统，全面消除水肿
静脉系统 1,2 微循环系统 3,1 淋巴系统1,4
1. Nicolaides A, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2008; 27:1 -59.
Vasc Surg 2008; 47:183-92. 3. Perrin M, Ramelet AA. Pharmacological Treatment of primary CVD, Eur J Vasc Endovasc Surg. 2011; 41:117-125. 4. Brennan MJ. Lymphedema following the surgical treatment of breast cancer: a review of pathophysiology and treatment. J
+++
+++
Albert Adrien RAMELET ，Management of chronic venous disease : the example of Daflon 500 mg， Phlebolymphology . Vol 16. No. 4. 2009，321-330
爱Fra Baidu bibliotek朗®安全性好
2. Amiel R, et al. Pharmacodynamic properties and therapeutic efficacy of Daflon 500mg. Phlebology. 1992; (2):41-44. 3. Perrin M, Ramelet AA. Pharmacological Treatment of primary CVD, Eur J Vasc Endovasc Surg. 2011; 41:117-125. 4. McHale NG, et al. Control of lymphatic pumping: interest of Daflon 500 mg. Phlebology. 1994; (suppl 1):23-25.